07:00 , Oct 7, 2013 |  BC Week In Review  |  Clinical News

Alefacept: Phase II data

Researchers at Indiana University and colleagues reported data from the double-blind, U.S. Phase II T1DAL1 trial in 49 evaluable patients with newly diagnosed Type I diabetes showing that once-weekly 15 mg intramuscular alefacept given as...
08:00 , Jan 11, 2010 |  BioCentury  |  Strategy

Evolution of Biogen Idec's Pipeline

Evolution of Biogen Idec's Pipeline For the first 20 years after its formation in 1978, Biogen Inc., now called Biogen Idec Inc. (NASDAQ:BIIB), followed an opportunistic R&D strategy, with a focus on immunology. In 1999, the...
08:00 , Jan 11, 2010 |  BioCentury  |  Strategy

Mulling over Biogen Idec's Future

One of Biogen Idec Inc.'s core dilemmas over the years, and one it has never resolved, is what it wanted to be after it grew up: a commercially driven enterprise or an R&D-driven company. With...
08:00 , Feb 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease...
07:00 , Jun 23, 2008 |  BioCentury  |  Regulation

Ustekinumab vs. other biologics

Ustekinumab vs. other biologics Compound [target] Safety issues (A) Study [pts] Dosing PASI 75 (B) In registration Ustekinumab [IL-12, IL-23] Notable safety issues discussed at last week’s FDA...
07:00 , Jun 23, 2008 |  BioCentury  |  Regulation

The Pastiche of risk

The discussion at last week’s Dermatologic and Ophthalmic Drugs Advisory Committee review of Johnson & Johnson’s ustekinumab to treat moderate-to-severe plaque psoriasis illustrates the tension in today’s regulatory environment for a compound that is clearly...
07:00 , Oct 8, 2007 |  BioCentury  |  Product Development

PASI 75 comparisons

PASI 75 comparisons PASI 75 comparisons Based on Phase III data announced last week for plaque psoriasis, Johnson & Johnson's ustekinumab (CNTO 1275) looks to be as good as the two best biologics - Humira...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Clinical News

Amevive alefacept: Phase II start

Astellas plans to begin an international Phase II trial of ASP045. The company acquired worldwide rights to the product, which it markets as Amevive alefacept to treat psoriasis, from Biogen Idec Inc. (BIIB, Cambridge, Mass.)...
07:00 , Aug 21, 2006 |  BioCentury  |  Product Development

Psoriasis meta-analysis

Psoriasis meta-analysis Daivobet/Taclonex Amevive Raptiva Enbrel PASI 50 88.8% 56.0% 59.0% 74.0% PASI 75 54.1% 28.0% 27.0% 49.0% Mean baseline PASI 22.6 15 (B) 19 18.4 Number of patients in analysis 268 (A) 367...
07:00 , Aug 21, 2006 |  BioCentury  |  Product Development

Challenging psoriasis biologics

Leo Pharma A/S is hoping that a recently published meta-analysis comparing its Daivobet ointment for severe psoriasis to Enbrel etanercept, Raptiva efalizumab and Amevive alefacept will make it easier to sell its product. This is...